4th Quarter - Report — CHAMBER HILL STRATEGIES for OS THERAPIES (2025)

Firm

CHAMBER HILL STRATEGIES

Client

OS THERAPIES

Income

—

Expenses

—

No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

cancer immunotherapy and antibody treatment; osteosarcoma

Lobbyist	Covered position, as disclosed
JENNIFER BELL	Health Policy Advisor, Sen. Finance Committee; Legislative Assistant, Rep. John Thune (R-SD)
SHAWN FRIESEN	Legislative Director, Rep. Mac Collins (R-GA)); Legislative Assistant, Rep. Tom Ewing (IL-15); Clerk, House Judiciary Committee
JENNIFER HOLLAND	Scheduler, Rep. Mary Kaptur (OH-09); Operations Director, Rep. Donald Norcross (NJ-01); Scheduler, Rep. Debbie Dingell (MI-06)

Contacted: SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Health Issues HCR

cancer immunotherapy and antibody treatment; osteosarcoma

Lobbyist	Covered position, as disclosed
JENNIFER BELL	Health Policy Advisor, Sen. Finance Committee; Legislative Assistant, Rep. John Thune (R-SD)
SHAWN FRIESEN	Legislative Director, Rep. Mac Collins (R-GA)); Legislative Assistant, Rep. Tom Ewing (IL-15); Clerk, House Judiciary Committee
JENNIFER HOLLAND	Scheduler, Rep. Mary Kaptur (OH-09); Operations Director, Rep. Donald Norcross (NJ-01); Scheduler, Rep. Debbie Dingell (MI-06)

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.